STOCK TITAN

Intuitive Surgical (ISRG) SVP sells 3,658 shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Intuitive Surgical senior executive Mark Brosius reported open-market sales of company common stock. As SVP and Chief Manufacturing and Supply Chain Officer, he sold a total of 3,658 shares across three transactions on March 3, 4, and 5, 2026.

The sales were executed at weighted-average prices of about $488.10, $498.6804, and $495.20 per share, with detailed price ranges provided in the footnotes. After these transactions, he directly held 2,906 shares of Intuitive Surgical common stock. All sales took place under a Trading Plan that complies with SEC Rule 10b5‑1 and expires on February 14, 2027.

Positive

  • None.

Negative

  • None.
Insider Brosius Mark
Role SVP & Chief Mfg and Supply Cha
Sold 3,658 shs ($1.82M)
Type Security Shares Price Value
Sale Common Stock 648 $495.20 $321K
Sale Common Stock 2,362 $498.6804 $1.18M
Sale Common Stock 648 $488.10 $316K
Holdings After Transaction: Common Stock — 2,906 shares (Direct)
Footnotes (1)
  1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $487.18 to $489.94 as follows: 432 shares sold at $487.18 and 216 shares sold at $489.94. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $495.19 to $500.00 as follows: 648 shares sold at $495.19 and 1,714 shares sold at $500.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brosius Mark

(Last) (First) (Middle)
1020 KIFER ROAD

(Street)
SUNNYVALE CA 94086

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INTUITIVE SURGICAL INC [ ISRG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & Chief Mfg and Supply Cha
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/03/2026 S(1) 648 D $488.1(2) 5,916 D
Common Stock 03/04/2026 S(1) 2,362 D $498.6804(3) 3,554 D
Common Stock 03/05/2026 S(1) 648 D $495.2 2,906 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $487.18 to $489.94 as follows: 432 shares sold at $487.18 and 216 shares sold at $489.94. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $495.19 to $500.00 as follows: 648 shares sold at $495.19 and 1,714 shares sold at $500.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
By: Stephanie Lim-Ignacio For: Brosius, Mark 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Mark Brosius report at Intuitive Surgical (ISRG)?

Mark Brosius reported selling common stock of Intuitive Surgical in three open-market transactions. These occurred on March 3, 4, and 5, 2026, and were executed under a pre-established SEC Rule 10b5-1 trading plan that outlines predetermined trading instructions.

How many Intuitive Surgical (ISRG) shares did Mark Brosius sell and over what dates?

He sold a total of 3,658 shares of Intuitive Surgical common stock. The transactions were 648 shares on March 3, 2,362 shares on March 4, and 648 shares on March 5, 2026, all reported as open-market sales on Form 4.

At what prices were the Intuitive Surgical (ISRG) shares sold by Mark Brosius?

The reported weighted-average sale prices were $488.10, $498.6804, and $495.20 per share. Footnotes explain that each sale consisted of multiple trades within specific ranges, and Brosius offers to provide full price breakdowns upon request to regulators or shareholders.

How many Intuitive Surgical (ISRG) shares does Mark Brosius hold after these sales?

Following the reported transactions, Mark Brosius directly holds 2,906 shares of Intuitive Surgical common stock. The Form 4 lists his ownership as direct, reflecting his remaining stake after the three open-market sales reported for early March 2026.

Was the Intuitive Surgical (ISRG) insider sale made under a 10b5-1 trading plan?

Yes. The filing states the transactions occurred under a Trading Plan that complies with SEC Rule 10b5-1. This plan, which pre-schedules trades, is disclosed as expiring on February 14, 2027, indicating the sales followed predetermined instructions.

What role does Mark Brosius hold at Intuitive Surgical (ISRG) according to the Form 4?

Mark Brosius is identified as an officer of Intuitive Surgical with the title “SVP & Chief Mfg and Supply Cha.” This indicates he serves as a senior vice president overseeing manufacturing and supply chain functions while engaging in the reported stock transactions.